NEXL Message Board - Msg: 12937000

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NEXL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Rick Costantino who wrote ()	2/22/2000 10:17:00 AM
From: John Grabiec	Read Replies (1) of 1704

Best NEXL DD.... from raginbull... ALL THE NEXL DUE DILIGENCE YOU NEED: NEXL Nexell Therapeutics Inc. (NASDAQ: NEXL) is THE LEADING DEVELOPER AND MARKETER OF INNOVATIVE DIAGNOSTICS AND EX VIVO CELL THERAPIES FOR CANCER, AUTOIMMUNE, METABOLIC AND GENETIC DISEASES. From a due diligence perspective, the stock has everything: > News out this morning. > Recently identified on CBS MarketWatch as having blockbuster potential; > Just completed $63 MILLION in financing; > Recognized as the industry leader and a major award winner; > Just launched a new cancer treatment process (huge potential); > Both insiders and institutions continue to accumulate; > 2 new licensing agreements; > Receiving excellent publicity. CEO starting to ?tell the story? at industry conferences; > Technical charts look excellent. > $5.50 to $6.00 currently. > Near term suggest: $10-12. $16-$20+ with pending developments. NOW FOR THE DETAILS. News out this morning regarding a new product launch: biz.yahoo.com The Company was recently identified as one of the BioTech companies that could become the next ?Blockbuster? on CBSMarketWatch. Of those identified, NEXL has the strongest balance sheet and most potential: cbs.marketwatch.com The Company recently completed a $63 MILLION (NOBODY INVESTS $63 MILLION UNLESS THE COMPANY HAS BLOCKBUSTER POTENTIAL) round of financing: biz.yahoo.com The Company has received leading industry awards recognizing its progress in cell therapy: biz.yahoo.com New products and distribution agreements: nexellinc.com nexellinc.com nexellinc.com nexellinc.com nexellinc.com Institutions continue to accumulate (300,000 shares net last quarter, Institutions have increased positions last 3 quarters in a row) insidertrader.com Insiders continue to accumulate: clearstation.com Recently entered into 2 worldwide licensing agreements with Diaclone, SA, a recognized leader in stem cell research: biz.yahoo.com The Company is receiving excellent publicity and the Company?s CEO, who is well respected within the sector, recently spoke at the BIO CEO & Investor Conference at the Waldorf-Astoria Hotel in New York City on 2/16: biz.yahoo.com biocognizance.com cellselection.com Technical charts for the company look excellent: quotes.barchart.com Other Information: Press Releases from Company website (must read): nexellinc.com nexellinc.com Company Mission and Profile (from webpage): nexellinc.com Company website: nexellinc.com Yahoo Profile: biz.yahoo.com Suggest $10-$12 near term. $16-20+ with pending releases or if word leaks further and momentum players enter the fray

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next